drugset / Trial / NCT04252118
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19
Phase 1
Unknown
20 enrolled
Beijing 302 Hospital
Fifth Affiliated Hospital, Sun Yat-Sen University · collabHuoshenshan Hospital · collabInnovative Precision Medicine Group (IPM), Hangzhou, China. · collabShenzhen Third People's Hospital · collabTianjin Haihe Hospital · collabVcanbio Cell and Gene Engineering Corp., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The SARS-CoV-2 infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected SARS-CoV-2, most of them should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions. This clinical trial is to inspect the safety and efficiency of Mesenchymal Stem Cells (MSCs) therapy for pneumonia patients infected with SARS-CoV-2.
Timeline
- Start
- 2020-01-27
- Primary completion
- 2020-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSCs | Cell therapy | 3e+07 cells | Intravenous |